communityacquir
pneumonia
cap
sixth
common
caus
death
unit
state
lead
caus
death
infecti
diseas
associ
signific
morbid
mortal
pose
major
econom
burden
healthcar
system
streptococcu
pneumonia
lead
caus
cap
common
bacteri
caus
includ
haemophilu
influenza
well
atyp
bacteria
mycoplasma
pneumonia
chlamydia
pneumonia
legionella
speci
increas
resist
varieti
antimicrobi
agent
document
pneumonia
common
h
influenza
well
success
empir
therapi
paramount
manag
cap
avoid
treatment
failur
subsequ
associ
cost
given
resist
increas
among
respiratori
pathogen
pneumonia
common
etiolog
agent
identifi
cap
strategi
antimicrobi
therapi
base
like
caus
pathogen
presenc
risk
factor
infect
resist
bacteria
local
resist
pattern
j
med
c
ommunityacquir
pneumonia
cap
common
infect
potenti
life
threaten
especi
older
adult
comorbid
diseas
cap
sixth
common
caus
death
unit
state
lead
caus
death
infecti
diseas
unit
state
approxim
million
physician
visit
annual
million
case
cap
nearli
adult
hospit
die
year
prognosi
cap
rang
rapid
recoveri
without
function
impair
seriou
complic
death
mortal
cap
approxim
hospit
nonsever
patient
outpati
addit
hospit
determin
intens
laboratori
evalu
antimicrobi
therapi
affect
overal
cost
cost
associ
manag
cap
inpati
set
significantli
burdensom
may
time
higher
associ
outpati
manag
overal
econom
burden
cap
signific
estim
total
cost
treat
patient
age
year
billion
year
half
total
cost
attribut
age
group
billion
patient
year
direct
expens
billion
per
year
attribut
inpati
cost
includ
hospit
length
stay
room
board
physician
servic
medicar
claim
data
demonstr
outpati
cost
total
million
patient
year
million
patient
year
birnbaum
colleagu
analyz
healthcar
data
employe
nation
fortun
compani
determin
employ
expens
employe
pneumonia
direct
indirect
cost
time
higher
patient
pneumonia
compar
pneumonia
vs
respect
addit
cost
could
attribut
patient
hospit
pneumonia
larg
econom
burden
result
inpati
treatment
therapi
conduc
outpati
treatment
may
like
produc
signific
save
sever
studi
shown
resist
pneumococc
infect
patient
requir
hospit
associ
increas
length
stay
mortal
cost
care
casecontrol
studi
iceland
demonstr
increas
cost
pneumonia
caus
penicillinresist
streptococcu
pneumonia
prsp
base
prolong
hospit
use
expens
antimicrobi
agent
result
recent
studi
new
york
hospit
conduct
demonstr
prsp
associ
longer
length
stay
day
vs
day
greater
total
direct
inpati
cost
vs
clearli
econom
consequ
associ
intens
manag
patient
infect
strain
pneumonia
resist
commonli
use
antimicrobi
observ
antimicrobi
resist
increas
number
like
caus
pathogen
led
challeng
manag
cap
clinician
consid
factor
select
empir
therapi
differ
clinic
sign
symptom
bacteri
viral
etiolog
clear
clinician
may
difficulti
distinguish
bacteri
viral
caus
infect
determin
whether
antimicrobi
therapi
warrant
obtain
uncontamin
specimen
suspect
infect
site
determin
whether
etiolog
bacteri
difficult
rare
done
even
specimen
obtain
microbiolog
result
inconclus
approxim
time
purpos
articl
updat
clinician
etiolog
cap
emphasi
commonli
identifi
pathogen
pneumonia
identifi
area
increas
concern
treatment
infect
provid
practic
consider
appropri
use
antimicrobi
therapi
light
increas
resist
sever
rout
pathogen
acquisit
involv
pathophysiolog
cap
aspir
oropharyng
content
common
rout
acquisit
often
consid
subclin
aspir
confus
aspir
pneumonia
anaerob
etiolog
pathophysiolog
pneumonia
involv
organ
descend
oropharynx
lower
respiratori
tract
rout
pathogen
acquisit
includ
inhal
spread
along
mucou
membran
virus
hematogen
spread
staphylococcu
contigu
spread
peopl
aspir
sleep
oropharyng
secret
enter
lower
respiratori
tract
varieti
defens
mechan
exist
airway
predominantli
anatom
barrier
eg
ciliari
action
aspir
materi
clinic
consequ
question
aris
aspir
result
clinic
pneumonia
alter
anatom
barrier
impair
ciliari
action
affect
inflammatori
mucu
product
upper
airway
occur
viral
infect
predispos
lower
airway
pneumonia
also
impair
normal
immun
system
either
humor
cellmedi
immun
phagocyt
function
could
result
organ
becom
pathogen
lower
respiratori
tract
pneumonia
usual
occur
breakdown
normal
host
defens
organ
extrem
virul
larg
inoculum
introduc
patient
experi
recurr
episod
pneumonia
certain
immun
system
defect
ie
human
immunodefici
viru
hiv
immunoglobulin
g
defici
consid
pneumococc
pneumonia
bacteri
pneumonia
bacteri
infect
occur
secondari
viral
infect
patient
damag
host
defens
therefor
viral
infect
signific
factor
lead
mani
secondari
bacteri
infect
microbiolog
etiolog
mani
studi
examin
etiolog
cap
virtual
studi
compil
trial
show
pneumonia
common
pathogen
case
follow
haemophilu
influenza
tabl
atyp
pathogen
mycoplasma
pneumonia
chlamydia
pneumonia
legionella
pneumophila
variabl
implic
depend
studi
virus
becom
appreci
common
caus
pneumonia
adult
patient
less
common
consider
eg
tuberculosi
pneumocysti
carinii
q
fever
fungi
sever
acut
respiratori
syndromeassoci
coronaviru
exist
clinician
also
consid
new
emerg
pathogen
potenti
caus
pneumonia
major
studi
evalu
etiolog
cap
consist
patient
hospit
laboratori
process
like
avail
diagnosi
howev
half
case
still
defin
etiolog
patient
stratifi
diseas
sever
ambulatori
hospit
nonsever
intens
care
unit
icu
sever
pneumonia
common
caus
cap
among
patient
set
tabl
studi
adult
patient
hospit
cap
counti
ohio
compar
incid
etiolog
agent
base
patient
age
shown
figur
incid
cap
requir
hospit
caus
pneumonia
pneumonia
l
pneumophila
increas
age
studi
spain
demonstr
patient
without
defin
etiolog
use
transthorac
needl
aspir
chang
rank
order
bacteria
caus
cap
compar
use
routin
cultur
serolog
mean
tabl
specif
pneumonia
becam
frequent
identifi
preval
pneumonia
case
h
influenza
identifi
use
aggress
techniqu
pathogen
identif
skin
needl
aspir
molecular
biolog
techniqu
polymeras
chain
reaction
improv
diagnost
accuraci
needl
aspir
led
posit
microbi
diagnosi
patient
compar
causal
convent
test
use
howev
unlik
use
transthorac
needl
aspir
becom
routin
practic
two
recent
studi
evalu
etiolog
mild
ambulatori
cap
common
pathogen
identifi
pneumonia
pneumonia
chlamydia
spp
virus
mostli
influenza
mycoplasma
common
patient
year
without
signific
comorbid
condit
abnorm
vital
sign
wherea
pneumonia
common
pathogen
older
patient
signific
underli
diseas
sever
popul
risk
develop
cap
includ
peopl
young
year
elderli
year
smoke
comorbid
ill
eg
chronic
obstruct
pulmonari
diseas
copd
diabet
mellitu
renal
insuffici
chronic
liver
diseas
heart
failur
coronari
arteri
diseas
chronic
neurolog
diseas
malign
mani
case
comorbid
may
affect
host
defens
mechan
previous
mention
thu
person
risk
factor
consid
microbiolog
diagnosi
andor
empir
therapi
broadspectrum
antimicrobi
minim
chanc
treatment
failur
patient
copd
particularli
risk
develop
pneumonia
clinic
manifest
acut
exacerb
copd
pneumonia
patient
similar
studi
patient
admit
hospit
acut
exacerb
found
pneumonia
note
although
h
influenza
common
caus
bacteri
exacerb
copd
common
pathogen
identifi
caus
pneumonia
pneumonia
patient
pneumonia
tend
hypoxem
higher
fever
abrupt
onset
higher
admitt
rate
icu
patient
often
requir
mechan
ventil
higher
mortal
longer
hospit
stay
clinic
present
pneumonia
bacteriolog
data
may
avail
time
diagnosi
pneumonia
typic
made
base
clinic
sign
symptom
patient
may
experi
chang
bodi
temperatur
hypothermia
fever
rigor
sweat
cough
without
product
sputum
alter
color
respiratori
secret
chest
discomfort
dyspnea
nonspecif
symptom
includ
fatigu
myalgia
abdomin
pain
anorexia
headach
also
may
present
addit
assess
physic
find
routin
examin
chest
xray
essenti
differenti
pneumonia
caus
symptom
assess
diseas
sever
strongli
recommend
recent
cap
guidelin
pneumococc
pneumonia
pneumococc
pneumonia
compris
two
third
case
bacteri
pneumonia
common
caus
morbid
patient
cap
pneumococc
pneumonia
common
form
cap
empir
antimicrobi
therapi
must
provid
coverag
pneumonia
consid
penicillinresist
strain
caus
pneumonia
patient
may
predisposit
pneumococc
infect
includ
young
old
nativ
american
smoker
sicklecel
diseas
hodgkin
diseas
myeloma
hiv
asplenia
alcohol
abnorm
immunoglobulin
product
respons
capsular
polysaccharid
may
also
greater
risk
may
predispos
form
pneumonia
addit
aforement
risk
factor
patient
particularli
risk
infect
prsp
includ
receiv
recent
antimicrobi
therapi
past
month
attend
daycar
immunodefici
institution
recent
hospit
sever
case
respond
empir
treatment
use
protect
specimen
brush
transthorac
needl
aspir
may
consid
effort
identifi
caus
pathogen
pathogen
part
reliabl
practic
differenti
patient
differ
etiolog
agent
base
clinic
manifest
alon
import
consider
select
empir
therapi
patient
develop
pneumonia
certain
paramet
predict
sever
consequ
particularli
mortal
sever
factor
may
increas
mortal
cap
tabl
find
associ
decreas
mortal
pleurit
chest
pain
may
alert
patient
presenc
problem
prompt
seek
treatment
earli
mortal
also
associ
cap
etiolog
metaanalysi
report
cap
publish
english
languag
mortal
rate
highest
gramneg
bacilli
pseudomona
aeruginosa
klebsiella
speci
escherichia
coli
staphylococcu
aureu
howev
preval
bacteria
much
lower
pneumonia
account
two
third
case
etiolog
diagnosi
made
also
account
major
cap
case
result
death
tabl
low
mortal
rate
report
coxiella
burnetii
pneumonia
wherea
pneumonia
mortal
rate
approach
averag
mortal
number
death
pneumococcu
far
surpass
number
pathogen
pneumonia
common
caus
pneumonia
also
common
caus
death
pneumonia
histor
clinician
prescrib
antimicrobi
empir
treatment
cap
littl
concern
suscept
suspect
pathogen
chosen
antimicrobi
howev
past
decad
increas
antimicrobi
resist
common
bacteri
pathogen
cap
especi
pneumonia
unit
state
h
influenza
isol
moraxella
catarrhali
isol
current
produc
result
resist
penicillin
mani
cephalosporin
disturb
howev
increas
rate
resist
level
resist
among
pneumonia
first
report
clinic
resist
pneumonia
penicillin
appear
nearli
year
introduct
penicillin
g
pneumococc
resist
penicillin
antimicrobi
document
south
africa
pneumococc
resist
report
mani
european
african
asian
countri
unit
state
strain
prsp
recov
surveil
program
conduct
center
diseas
control
prevent
cdc
howev
sharp
increas
preval
prsp
occur
unit
state
earli
figur
n
suscept
penicillin
similar
trend
increas
pneumonia
resist
penicillin
observ
worldwid
particular
concern
select
appropri
antimicrobi
treatment
cap
increas
preval
highlevel
resist
multidrug
resist
document
pneumonia
highlevel
penicillin
resist
ie
penicillin
minimum
inhibitori
concentr
mic
gml
among
pneumonia
increas
greater
degre
past
year
intermedi
resist
mic
gml
figur
g
v
doern
person
commun
decemb
addit
penicillin
resist
isol
pneumonia
demonstr
increas
resist
class
antimicrobi
includ
macrolid
tetracyclin
trimethoprimsulfamethoxazol
tmpsmx
fluoroquinolon
unit
state
preval
resist
newer
macrolid
eg
azithromycin
clarithromycin
among
pneumonia
isol
similar
erythromycin
approxim
observ
regard
macrolideazalid
resist
coupl
recent
report
clinic
failur
azithromycin
clarithromycin
pneumococc
pneumonia
bacteremia
resist
fluoroquinolon
antimicrobi
also
increas
recent
year
resist
ofloxacin
increas
isol
obtain
activ
bacteri
core
surveil
program
cdc
furthermor
data
alexand
project
demonstr
pneumonia
isol
unit
state
resist
ofloxacin
preval
pneumococc
isol
canada
reduc
suscept
fluoroquinolon
increas
recent
canadian
studi
pneumonia
respiratori
isol
elderli
patient
year
tang
colleagu
report
resist
rate
levofloxacin
similarli
resist
fluoroquinolon
hong
kong
increas
period
ofloxacin
levofloxacin
fluoroquinolon
resist
manifest
clinic
recent
report
levofloxacin
treatment
failur
patient
levofloxacinresist
pneumonia
infect
crossresist
complic
select
antimicrobi
therapi
multidrug
resist
crossresist
antimicrobi
common
pneumonia
among
outpati
pneumonia
respiratori
isol
evalu
recent
surveil
program
unit
state
suscept
penicillin
intermedi
resist
highli
resist
pneumonia
isol
intermedi
fulli
resist
penicillin
respect
also
resist
macrolid
azalid
anoth
studi
evalu
pattern
resist
isol
patient
pneumococc
pneumonia
isol
suscept
penicillin
resist
erythromycin
tmpsmx
respect
among
penicillinresist
isol
resist
cefotaxim
erythromycin
tmpsmx
respect
factor
may
drive
resist
includ
antimicrobi
consumpt
particularli
antimicrobi
use
past
month
inappropri
use
antimicrobi
eg
suboptim
dosag
clonal
spread
multidrugresist
strain
presenc
comorbid
antimicrobi
prescrib
habit
affect
resist
pattern
antimicrobi
overus
contribut
resist
studi
spain
demonstr
increas
use
penicillin
associ
increas
penicillinnonsuscept
isol
figur
hyde
colleagu
demonstr
use
macrolid
children
associ
increas
macrolid
resist
similarli
chen
colleagu
show
increas
use
ciprofloxacin
canada
correl
emerg
ciprofloxacin
resist
among
pneumococci
result
hong
kong
demonstr
patient
previous
expos
fluoroquinolon
time
like
acquir
levofloxacinresist
isol
pneumonia
recent
inappropri
use
antimicrobi
also
independ
risk
factor
develop
resist
studi
guillemot
colleagu
use
within
previou
day
odd
ratio
confid
interv
ci
dose
lower
clinic
recommend
ci
treatment
day
ci
identifi
risk
factor
penicillinresist
pneumococc
nasopharyng
carriag
recent
studi
yu
colleagu
evalu
clinic
relev
bacterem
pneumococc
pneumonia
underli
factor
associ
develop
resist
factor
shown
independ
associ
resist
multivari
analysi
underli
diseas
ie
heart
liver
renal
lung
diseas
diabet
p
prior
antimicrobi
therapi
p
strain
bacteria
develop
resist
resist
spread
especi
presenc
extens
use
antimicrobi
total
drugresist
pneumonia
drsp
strain
unit
state
caus
differ
serotyp
domin
factor
emerg
prsp
unit
state
result
humantohuman
spread
clonal
group
clinic
relev
drsp
mening
well
understood
know
adequ
antimicrobi
concentr
cerebrospin
fluid
csf
must
attain
kill
bacteria
site
high
concentr
overcom
low
level
resist
penicillin
breakpoint
defin
base
csf
concentr
mic
gml
consid
suscept
mic
gml
intermedi
mic
gml
resist
cap
clinic
relev
resist
less
well
understood
recent
data
mortal
rate
penicillinsuscept
versu
pneumonia
conflict
studi
control
potenti
confound
factor
eg
age
underli
diseas
sever
ill
shown
differ
mortal
patient
penicillinsuscept
pneumococci
prsp
howev
difficult
studi
advers
impact
drug
resist
clinic
outcom
patient
pneumococc
pneumonia
patient
receiv
antimicrobi
therapi
isol
suscept
furthermor
mani
studi
includ
pneumonia
isol
intermedi
suscept
penicillin
may
clinic
relev
regard
patient
outcom
cap
infect
highli
resist
mic
gml
isol
numer
studi
conduct
unabl
consist
show
correl
mortal
resist
demonstr
penicillin
resist
clinic
relev
ie
associ
clinic
failur
howev
studi
includ
isol
intermedi
suscept
resist
group
word
resist
group
nonsuscept
group
suscept
group
fact
two
third
resist
group
includ
isol
intermedi
suscept
prospect
studi
spain
mortal
correl
resist
even
though
resist
penicillin
cephalosporin
erythromycin
increas
studi
period
contrast
sever
studi
shown
signific
associ
mortal
highlevel
penicillin
resist
mic
gml
pneumonia
studi
cdc
investig
found
hospit
day
risk
death
time
greater
patient
infect
highlevel
prsp
mic
gml
ci
patient
infect
intermedi
isol
mic
gml
ci
howev
treatment
sever
diseas
record
similarli
anoth
studi
demonstr
penicillin
resist
mic
gml
independ
predictor
mortal
patient
pneumococc
bacteremia
trial
patient
medic
outcom
inhospit
mortal
medic
complic
rate
time
clinic
stabil
patient
bacterem
pneumococc
pneumonia
caus
penicillinsuscept
strain
pneumonia
compar
patient
infect
pnsp
compar
patient
infect
penicillinsuscept
strain
patient
infect
pnsp
mic
gml
greater
risk
inhospit
death
pneumonia
rel
risk
rr
ci
figur
addit
risk
suppur
complic
infect
increas
patient
infect
pnsp
rr
ci
howev
adjust
baselin
differ
sever
ill
risk
suppur
complic
infect
remain
statist
signific
adjust
rr
ci
studi
associ
identifi
age
sever
ill
comorbid
whether
isol
prsp
similar
result
found
followup
casecontrol
studi
patient
bacterem
pneumococc
pneumonia
address
limit
trial
feikin
colleagu
control
risk
factor
sever
treatment
find
multivari
analysi
show
contribut
antimicrobi
resist
mortal
requir
icu
determin
import
predictor
outcom
includ
sever
ill
whether
resuscit
order
patient
chart
light
increas
antimicrobi
resist
among
pneumonia
common
respiratori
pathogen
physician
must
consid
local
epidemiolog
resist
pattern
patient
risk
factor
infect
drugresist
pathogen
like
infect
pathogen
select
appropri
therapi
strategi
therapi
cap
must
take
account
fact
pneumonia
common
etiolog
agent
ambulatori
hospit
nonicu
sever
icu
set
gener
empir
therapi
case
cap
cover
key
respiratori
pathogen
atyp
pathogen
sever
guidelin
treatment
cap
develop
aid
physician
select
appropri
therapi
guidelin
infecti
diseas
societi
america
idsa
emphas
pathogendirect
treatment
strongli
suspect
determin
etiolog
empir
antimicrobi
therapi
consid
sever
ill
like
etiolog
agent
resist
pattern
among
pneumonia
commonli
identifi
pathogen
comorbid
import
stratifi
patient
appropri
use
antimicrobi
tabl
patient
without
signific
comorbid
recent
use
antimicrobi
macrolid
doxycyclin
prefer
howev
patient
greater
risk
drsp
respiratori
fluoroquinolon
combin
therapi
plu
macrolid
atyp
coverag
recommend
prefer
list
highdos
amoxicillin
either
amoxicillin
gday
amoxicillinclavulan
g
bid
similarli
guidelin
american
thorac
societi
suggest
empir
therapi
base
like
infect
pathogen
combin
therapi
oral
cefpodoxim
cefuroxim
highdos
amoxicillin
amoxicillinclavulan
plu
macrolid
doxycyclin
atyp
coverag
monotherapi
respiratori
symposium
streptococcu
pneumonia
communityacquir
pneumoniafil
jr
fluoroquinolon
indic
outpati
cardiopulmonari
diseas
congest
heart
failur
copd
andor
modifi
factor
place
risk
infect
drsp
gramneg
pathogen
anoth
set
recommend
cap
develop
drugresist
streptococcu
pneumonia
therapeut
work
group
cdc
emphas
treatment
suspect
etiolog
pneumonia
suggest
con
sider
strain
resist
penicillin
group
recommend
oral
good
pneumococc
coverag
ie
cefuroxim
axetil
amoxicillin
amoxicillinclavulan
outpati
treatment
cap
acknowledg
agent
effect
atyp
pathogen
altern
outpati
antimicrobi
treatment
includ
macrolid
doxycyclin
fluoroquinolon
list
cdc
group
firstlin
agent
concern
emerg
resist
new
pharmacokinet
enhanc
extendedreleas
formul
inhibitor
combin
amoxicillinclavulan
mg
bid
may
appropri
therapi
outpati
cap
particularli
risk
infect
pneumonia
isol
resist
penicillin
extendedreleas
amoxicillinclavulan
provid
time
mic
valu
unattain
older
formul
isol
penicillin
mic
gml
perhap
gml
addit
clavulan
compon
abil
inhibit
enzym
provid
coverag
h
influenza
catarrhali
possibl
caus
cap
formul
shown
effect
pneumonia
isol
mic
gml
promis
result
isol
mic
gml
data
patient
clinic
trial
acut
bacteri
sinus
cap
acut
exacerb
chronic
bronchiti
extendedreleas
amoxicillinclavulan
evalu
success
rate
pneumonia
erad
show
rel
penicillin
mic
success
clinic
outcom
note
patient
pathogen
isol
amoxicillin
mic
gml
good
clinic
respons
seen
higher
mic
erad
mic
gml
mic
gml
extendedreleas
amoxicillinclavulan
effect
erythromycinresist
isol
isol
test
patient
cap
treat
outpati
clinician
must
cogniz
etiolog
agent
cap
local
antimicrobi
sensit
pattern
pharmacolog
option
empir
therapi
treatment
cap
becom
increasingli
complic
time
despit
develop
newer
broaderspectrum
antimicrobi
agent
pneumonia
common
caus
cap
empir
therapi
target
pathogen
consid
drugresist
isol
speci
even
list
potenti
bacteriolog
etiolog
grow
treatment
cap
continu
empir
difficulti
obtain
uncontamin
specimen
differenti
colon
bacteria
caus
infect
serolog
cultur
result
rapid
often
fail
identifi
caus
pathogen
high
rate
bacteri
resist
antimicrobi
particularli
among
pneumonia
limit
avail
therapeut
option
time
option
need
distinguish
nonbacteri
bacteri
etiolog
respiratori
tract
infect
eg
mild
cap
viral
bronchiti
major
challeng
physician
clinic
distinguish
criteria
clear
marker
recommend
avail
guid
physician
decis
make
judici
prescrib
antimicrobi
therapi
warrant
good
clinic
practic
also
necessari
curtail
current
pattern
increas
bacteri
resist
commonli
use
antimicrobi
choic
antimicrobi
suspect
infect
bacteri
etiolog
made
base
like
pathogen
particular
patient
likelihood
organ
resist
given
pneumonia
common
caus
cap
penicillin
resist
increas
pathogen
extendedreleas
amoxicillinclavulan
appropri
antimicrobi
patient
cap
infect
known
suspect
prsp
addit
patient
educ
expect
benefit
minim
use
antimicrobi
therapi
infect
suspect
viral
etiolog
new
specimensampl
techniqu
microbiolog
detect
method
becom
avail
shift
empir
therapi
toward
pathogendirect
therapi
may
result
improv
outcom
curb
antimicrobi
resist
